Merck & Co. Number of Exercisable Options increased by 1.2% to $244.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.2%, from $241.00M to $244.00M. Over 5 years (FY 2020 to FY 2025), Number of Exercisable Options shows a downward trend with a -4.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A high number indicates significant potential for future share issuance and dilution as employees exercise their vested options.
This metric counts the number of share-based payment options that have vested and are currently available for employees...
Standard disclosure in equity compensation footnotes for all public companies.
options_exercisable_number| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $198.00M | $399.00M | $379.00M | $241.00M | $244.00M |
| QoQ Change | — | +101.5% | -5.0% | -36.4% | +1.2% |
| YoY Change | — | +101.5% | -5.0% | -36.4% | +1.2% |